Higher Share of Chronic, which provides a stable stream of revenues coupled with sustained traction from the top brands and margin expansion, due to favorable mix, to lead to double digit earnings growth over CY2019-CY2022E. Better growth prospects, low exposure to regulated markets, strong balance sheet, healthy cashflows, would continue to support premium valuations. Sanofi India (Sanofi), reported mixed performance for the quarter. Though the numbers are not comparable with the previous quarters as the company had hived off its Ankleshwar facility. The revenues for the quarter declined 11.9% y-o-y to Rs 687 crore...